CN1562057A - Medicinal composition for treating cardiocerobral diseases - Google Patents
Medicinal composition for treating cardiocerobral diseases Download PDFInfo
- Publication number
- CN1562057A CN1562057A CN 200410022178 CN200410022178A CN1562057A CN 1562057 A CN1562057 A CN 1562057A CN 200410022178 CN200410022178 CN 200410022178 CN 200410022178 A CN200410022178 A CN 200410022178A CN 1562057 A CN1562057 A CN 1562057A
- Authority
- CN
- China
- Prior art keywords
- radix astragali
- puerarin
- astragali saponin
- saponin
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
A composite medicine for treating cardiovascular and cerebrovascular diseases contains kakonein and astragaloside.
Description
Affiliated technical field
The present invention relates to a kind of medicine for the treatment of cardiovascular and cerebrovascular disease, specifically the pharmaceutical composition of the effective site of the puerarin and Radix Astragali composition.
Background technology
Motherland's medical science is thought, " qi being the governor of blood, blood being the material foundation of QI ", the capable then blood of gas is capable, and blood operation freely can not have influence on the biochemistry operation of gas yet, so when the treatment relevant disease, general opinion is used Qi-tonifying drug and blood circulation promoting medicine compatibility, to reach the effect that QI and blood is ruled together.
The Radix Astragali be a benefiting QI for strengthening the superficies, to heart have protective effect, can human body immunity improving the Chinese medicine of function.It mainly contains saponin, polysaccharide, contains compositions such as aminoacid, flavone in addition.Radix Astragali saponin has the myocardium shrinkage function of improvement to the anxious Terrier heart, dwindles myocardial infarction area, alleviates the effect of myocardial damage; Radix Astragali saponin can effectively improve myocardial ischemia, and the protection cardiovascular and cerebrovascular vessel are improved heart microcirculation.Its main onset composition is an astragaloside.Astragaloside content is very low in the existing Milkvetch Root, is about 0.04%.Existing commercially available Radix Astragali injection, the Radix Astragali injection of producing as Chengdu buchu, Fuda, Shanghai etc., because technological reason generally adopts water to carry repeatedly alcohol deposition method, and that water is carried the extraction ratio of Radix Astragali saponin is lower, and filtration ratio difficulty, stops up filter cloth slowly and easily, not easy to operate; The loss of Radix Astragali saponin is also bigger during precipitate with ethanol, thereby the content of Radix Astragali saponin is lower in the preparation.In addition, existing Radix Astragali injection QI invigorating effect is stronger, and the effect of invigorating blood circulation is relatively poor.
Puerarin has function of promoting blood circulation to disperse blood clots preferably, cerebrovascular circulates to improving, the cerebral blood flow increasing amount has obvious effects, it is effective preparation of treatment cerebral infarction, in recent years find, this product also has good dilating effect to cardiovascular, can reduce Peripheral resistance, reduce myocardial oxygen consumption, promote collateral circulation, suppress platelet aggregation, angina pectoris is had curative effect preferably.Existing puerarin injection has function of promoting blood circulation to disperse blood clots preferably, but its no QI invigorating effect.
Summary of the invention
Purpose of the present invention just provides a kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease, and this pharmaceutical composition can activating blood circulation to dissipate blood stasis, again can replenishing qi and promoting blood flow, and QI and blood is ruled together, and produces synergism, raising evident in efficacy.
The technical solution adopted for the present invention to solve the technical problems is: a kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease, it is made up of puerarin and two kinds of raw materials of Radix Astragali saponin of extracting from the Radix Astragali.
Medicine of the present invention raw materials used weight proportion can be 1 part of the Radix Astragali saponin that extracts, puerarin 0.1-20 part from the Radix Astragali.
The raw materials used optimum ratio of medicine of the present invention is: 1 part of the Radix Astragali saponin that extracts from the Radix Astragali, puerarin 0.2-15 part.
The raw materials used more preferably proportioning of medicine of the present invention is: 1 part of the Radix Astragali saponin that extracts from the Radix Astragali, puerarin 2-12 part.
The raw materials used best proportioning of medicine of the present invention is: 1 part of the Radix Astragali saponin that extracts from the Radix Astragali, 10 parts of puerarins.
The dosage form of medicine of the present invention can be any existing pharmaceutical dosage form in injection, transfusion, powder pin, drop pill, tablet, slow releasing tablet, capsule, soft capsule, the granule.
The cardiovascular and cerebrovascular disease that medicine of the present invention is controlled mainly comprises cerebral thrombosis, cerebral ischemia, coronary heart disease, angina pectoris, myocardial ischemia, heart failure, arrhythmia etc.
Pharmaceutical composition of the present invention is made various dosage forms by existing preparation process after can adopting conventional method with puerarin and Radix Astragali saponin uniform mixing.The commercial goods of puerarin for can directly buying in the raw material; Radix Astragali saponin can adopt following method to extract from the Radix Astragali: get Milkvetch Root, use ethanol extraction, collect extracting solution, in the extracting solution after reclaiming ethanol, thin up staticly settles, and filters, and gets supernatant concentration and becomes extractum; Described extractum is crossed macroporous adsorbent resin, and the low-concentration ethanol eluting of first water or 5-20% is removed the impurity that is dissolved in polar solvent, discard need not, the high concentration ethanol eluting of reuse 40-95% is collected this high concentration ethanol eluent, eluent drying with behind the recovery ethanol promptly gets Radix Astragali saponin.
Compared with prior art, the invention has the beneficial effects as follows: this pharmaceutical composition contains puerarin and Radix Astragali saponin, it can activating blood circulation to dissipate blood stasis, again can replenishing qi and promoting blood flow, QI and blood is ruled together, produce synergism, than singly using with the dosage puerarin or singly using effect all to improve greatly, prove that through pharmacodynamics test it is evident in efficacy with the dosage Radix Astragali saponin.
The curative effect of medicine of the present invention is proved by following pharmacodynamics test:
Because cardiovascular and cerebrovascular disease all can cause hemorheological change, so can design puerarin and Radix Astragali saponin cause the therapeutical effect of cerebral infarction to rat " rabbit brain powder-macromolecule glucosan " pharmacodynamics test, investigate the change of hemorheological property behind the cerebral infarction to measure whole blood viscosity under the different shear rates, investigate erythrocyte deformability with erythrocyte albumen ringer solution viscosity, thereby investigation puerarin and Radix Astragali saponin are to the therapeutical effect of cardiovascular and cerebrovascular disease.
Material: animal: rat, body weight 250-350g, male and female are regardless of.Equipment: cone and plate viscometer (homemade NZ-6 type), centrifuge, scale centrifuge tube, eye scissors, ophthalmology tweezer and operating theater instruments commonly used, 0 trumpeter's art silk thread, vascular clamp etc.Medicine and reagent: (puerarin/Radix Astragali saponin is respectively the different proportionings of puerarin and Radix Astragali saponin: medicine 10/0,20/1,15/1,10/1,5/1,3/1,1/1,0/10); With commercially available puerarin injection, the positive medicine contrast of Radix Astragali injection; Rabbit brain powder (rabbit brain powder thromboplastin powder), the biochemical reagents experiment of Shanghai section is produced.Get the rabbit brain powder between the sub-sieve 120-150 order, granule is 100-120m.Macromolecule glucosan: molecular weight 5,000,000.The preparation of suppository: the 25mg rabbit brain powder is mixed in 10% macromolecule dextran solution 100ml, place 37 ℃ of water-baths 40 minutes.Then, it is standby to be put in-18 ℃ of refrigerators.Quick medical ZT glue (Xi'an Research Inst. of Chemical Industry's production).BSA, ringer solution.Heparin sodium: press 20u/ml blood dosage and add test tube, 40 ℃ of following dry for standby.
Test method: 1, the rat cerebral infarction model prepares: the rat etherization, and it is fixing to lie on the back, skin cropping sterilization, cervical region cuts, and neck always beats one's brains on the left of separating, neck is interior, external carotid artery.Folder closes external carotid artery, common carotid artery proximal part respectively.Press from both sides a vascular clamp again at the distal end place.After suppository shaken up, lunge common carotid artery by 0.03ml/100g rat dosage, open the distal end vascular clamp, suppository is injected with the 0.25ml syringe.Then, folder closes the common carotid artery distal end, extracts syringe needle, closes pin hole with medical adhesive dressing.Decontrol the vascular clamp of common carotid artery distal end, proximal part, external carotid artery after 1 minute successively, recover blood flow, cleaning wound, skin suture.
The different proportioning medicines of puerarin/Radix Astragali saponin to cerebral infarction after the hemorheology influence of different time: rat is divided into 2 hours groups, 3 days groups, organized in 9 days, every group is further divided into administration group (the different proportioning medicines of puerarin/Radix Astragali saponin+animal model group), normal saline group (normal saline+animal model group), sham operated rats (matched group), every group of 12 rats.Administration group, normal saline group all impose operation technique as stated above, and the sham operated rats operation technique is identical, but not injected plug agent with the physiologic saline for substitute suppository, is injected in internal carotid artery.
The administration group is in preceding 1 hour intraperitoneal injection of drugs (puerarin/Radix Astragali saponin, positive drug) 1.0mg/Kg of operation.The normal saline group is injected commensurability normal saline.Sham operated rats is not injected any medicine.Every morning administration 1 time after 3 days groups and the 9 days groups, for three days on end or 9 days.
2 hours after surgery, the 3rd day, the 9th day respectively, with rat anesthesia (25% urethane 0.3ml/100g body weight, lumbar injection), the right common carotid artery blood-letting was measured whole blood viscosity under the different shear rates with cone and plate viscometer in 2 hours in the heparin test tube.Again that whole blood is centrifugal with 1500rpm, inhale and remove upper plasma.Use 0.25% bovine serum albumin-ringer solution rinsing erythrocyte then three times, centrifugal 10 minutes of each 1500rpm.At last, in vitro be mixed with erythrocyte at scale: albumen is appointed the erythrocyte albumen ringer solution of liquid=6: 4, measures its viscosity at 20 seconds-1 under the shear rate.With erythrocyte albumen ringer solution viscosity as erythrocyte deformability.All experiments are all carried out under 25 ℃ of constant temperature, and experimental result is carried out statistical test.Concrete numerical value and the results are shown in Table one, table two.
Table one: the puerarin of different proportionings and Radix Astragali saponin medicine (injection) are to the whole blood viscosity influence (unit: mPa.s) of different time behind the rat cerebral infarction
| Radix Puerariae is cut element: xanthochromia stilbene saponin rate | ????????2h | ????????3d | ????????????????????????????????????????????????????9d |
| Normal saline administration group matched group group | Normal saline administration group matched group group | Normal saline administration group matched group group | |
| ??????????100s -110∶0?????20s -1??????????10s -1 | 7.72±22???????721±0.7??????7.17±0.8?????????????????????9.98±22????????9.62±2.2???????8.62±2.0 ***???????????????20.94±0.8?????9.21±2.2 **?????????9.02±0.9 ***12.12±3.2?????12.99±2.0????12.01±2.1????????????????????17.07±2.4??????15.49±2.2??????14.27±2.8 **???????????????20.29±2.8?????17.98±3.6 **???????11.42±2.0 ***42.26±18.2????37.64±8.1????36.89±14.1???????????????????82.72±24.7?????65.10±16.6?????49.84±22.2 **??????????????94.06±20.2????86.82±22.2?????????56.29±12.8 *** | ||
| ??????????100 -120∶1?????20 -1??????????10 -1 | 7.71±1.0??????7.22±0.2?????7.14±2.2?????????????????????10.97±1.6??????8.12±2.6 **????8.61±2.2 ***???????????????11.14±0.9?????9.01±1.1 ***????????9.04±0.8 ***12.20±3.4?????10.79±2.6????10.78±2.6????????????????????17.06±2.6??????11.29±4.6??????14.07±2.8 **???????????????19.22±2.6?????17.78±4.6 **???????11.82±2.6 ***42.26±17.2????30.64±9.8????31.89±12.1???????????????????80.68±22.7?????51.10±18.6 **??46.24±22.2 **??????????????92.86±19.2????62.80±21.2 **??????51.89±11.4 *** | ||
| ??????????100s -115∶1?????20 -1??????????10 -1 | 7.79±0.2??????7.22±0.8?????7.67±0.8?????????????????????9.67±2.6???????8.22±2.8 **????8.21±1.2 ***???????????????10.64±0.7?????9.02±1.4 ***????????9.22±0.8 ***12.00±3.2?????10.19±2.0????12.01±2.1????????????????????17.22±2.6??????14.70±2.1 **???14.64±2.2 **???????????????19.67±2.4?????14.98±3.6 ***??????11.24±1.8 ***42.26±18.2????30.04±8.8????31.89±14.1???????????????????82.70±21.7?????51.06±16.6 **??51.14±17.2 **??????????????96.24±17.8????51.14±27.1 ***?????56.14±14.2 *** | ||
| ??????????100s -110∶1?????20s 1??????????10 -1 | 7.76±1.2??????7.26±0.7?????7.17±0.7?????????????????????9.67±2.1???????8.12±1.1.1 **??8.27±1.1 ***???????????????10.22±0.9?????8.46±0.8 ***????????9.07±0.9 ***12.2±2.2??????10.92±2.2????10.41±2.1????????????????????17.16±2.2??????14.22±1.1 **???14.27±2.8 **???????????????19.98±2.1?????14.22±2.8 ***??????11.28±2.6 ***39.26±26.2????34.64±8.7????32.89±12.1???????????????????81.94±18.7?????50.22±14.6 **??49.84±22.1 **??????????????92.16±21.2????52.46±18.2 ***?????51.24±18.7 *** | ||
| ??????????100s -15∶1??????20s -1??????????10s -1 | 7.79±1.2??????7.92±0.7?????7.24±0.8?????????????????????10.27±1.6??????8.00±1.0 ***???8.21±1.6 ***???????????????10.44±0.8?????8.02±0.6 ***????????9.01±0.9 ***12.22±3.2?????10.69±2.0????10.61±2.2????????????????????17.87±1.9??????14.01±1.8 ***??14.04±1.8 **???????????????20.22±2.6?????12.48±6.0 ***??????11.22±2.6 ***40.62±18.2????39.84±8.8????34.84±161????????????????????82.20±22.6?????48.02±11.2 ***?49.68±17.4 **??????????????92.24±20.7????47.26±24.7 ***?????51.22±17.8 *** | ||
| 100s -13: 1 20s 110s -1 | 8.04 ± 1.9 7.82 ± 06 7.12 ± 0.6 9.86 ± 1.6 8.22 ± 1.2 * *8.22 ± 1.2 * *10.24 ± 1.2 8.26 ± 1.2 * *8.96 ± 0.2 * *12.42 ± 2.2 10.12 ± 1.0 10.24 ± 1.2 17.46 ± 2.2 13.91 ± 2.6 * *14.02 ± 2.2 *19.838 ± 2.6 16.64 ± 3.7 * *11.02 ± 2.2 * *40.24 ± 16.2 38.82 ± 7.8 34.79 ± 12.1 82.21 ± 22.7 48.42 ± 16.6 * *49.24 ± 14.2 *92.99 ± 24.8 52.86 ± 24.0 * *56.47 ± 11.0 * * |
| 100s -11: 1 20s -110s -1 | 7.77 ± 1.2 7.24 ± 0.7 7.02 ± 0.1 9.92 ± 0.8 8.42 ± 1.0 *8.42 ± 1.7 *10.74 ± 1.9 9.16 ± 1.0 *9.04 ± 0.7 * *12.26 ± 2.7 11.68 ± 2.6 10.21 ± 1.7 17.12 ± 1.9 14.99 ± 2.2 *14.40 ± 2.4 *19.62 ± 2.2 11.98 ± 3.4 *11.98 ± 2.4 * *42.22 ± 14.6 36.44 ± 14.9 31.41 ± 12.1 82.22 ± 22.7 61.62 ± 16.6 49.64 ± 18.2 *92.61 ± 24.7 67.14 ± 27.0 *56.02 ± 13.2 * * |
| 100s -10: 10 20s -110s -1 | 7.61 ± 1.4 7.64 ± 0.1 7.27 ± 0.2 9.18 ± 1.2 9.62 ± 1.0 8.17 ± 1.6 *10.47 ± 0.7 9.86 ± 12 9.02 ± 0.7 * *16.01 ± 1.2 12.88 ± 2.1 12.21 ± 1.4 17.67 ± 2.4 16.19 ± 2.6 14.24 ± 2.2 *19.61 ± 2.7 17.91 ± 2.8 11.81 ± 2.4 * *40.26 ± 16.2 31.66 ± 7.9 36.89 ± 22.1 82.28 ± 21.7 69.99 ± 12.9 50.44 ± 20.6 *92.89 ± 27.6 78.89 ± 22.4 56.22 ± 17.2 * * |
| The Radix Astragali is annotated 100s -1Penetrate liquid 20s -110s -1 | 7.76 ± 2.6 7.42 ± 0.7 7.24 ± 0.1 10.27 ± 1.4 9.46 ± 2.1 8.62 ± 1.1 *10.24 ± 0.4 9.% ± 2.7 9.14 ± 2.4 * *12.62 ± 2.2 10.14 ± 2.6 12.21 ± 1.1 17.14 ± 2.6 16.02 ± 2.8 14.62 ± 2.8 *19.14 ± 2.4 18.79 ± 4.0 11.14 ± 2.4 * *42.46 ± 11.1 36.66 ± 12.9 37.29 ± 17.1 82.24 ± 26.7 74.40 ± 16.8 49.84 ± 22.2 *92.72 ± 18.2 83.86 ± 22.7 54.24 ± 12.2 * * |
| Puerarin 100s -1Injection 20s -110s -1 | 8.27 ± 2.1 8.22 ± 1.2 7.16 ± 0.8 9.44 ± 2.1 9.42 ± 2.0 8.27 ± 1.4 *10.11 ± 2.7 9.41 ± 2.7 9.00 ± 0.8 * *12.61 ± 2.2 10.68 ± 2.2 10.01 ± 2.6 17.61 ± 2.6 21.09 ± 2.7 *14.07 ± 2.8 *20.29 ± 2.4 16.98 ± 3.4 *15.72 ± 2.3 * *42.21 ± 17.1 37.61 ± 9.9 34.49 ± 14.1 82.70 ± 25.7 61.10 ± 26.2 49.14 ± 24.1 *89.07 ± 272 64.16 ± 24.2 *56.24 ± 24.7 * * |
| Annotate: *P＜0.05 * *All compare with the normal saline group P＜0.01. | |
</entry></row></tbody></tgroup></table></tables>By table one result of the test as can be known, block back 2 hours after, whole blood viscosity is respectively organized equal no significant difference.When blocking 3 days, the normal saline group is compared with sham operated rats, whole blood viscosity rising (P＜0.01), animal model modeling success is described, each administration group all can reduce whole blood viscosity to some extent, wherein with puerarin/Radix Astragali saponin 11/1,10/1,1/1,3/1 effect best (P＜0.01), puerarin/Radix Astragali saponin 20/1,1/1 effect is taken second place, and puerarin uses than single with puerarin or single effective with Radix Astragali saponin with the Radix Astragali saponin proportioning.When blocking after 9 days, the normal saline group is an abnormality still with sham operated rats ratio, hemorheology, and whole blood viscosity further increases the weight of.Each administration group and normal saline group ratio, whole blood viscosity descends, statistical procedures has the significance meaning, wherein with puerarin/Radix Astragali saponin 11/1,10/1,1/1,3/1 effect best (P＜0.01), puerarin/Radix Astragali saponin 20/1,1/1 effect is taken second place, puerarin uses than single with the Radix Astragali saponin proportioning uses Radix Astragali saponin effective with puerarin or list, and effect all is better than puerarin injection and Radix Astragali injection.
By table two result of the test as can be known, block back 2 hours after, normal saline group and administration group erythrocyte deformability descend, each administration group is lower slightly than normal saline group numerical value, but effect is very unobvious.When blocking 3 days, the normal saline group is compared with sham operated rats, erythrocyte deformability further descends, in each administration group, puerarin/Radix Astragali saponin 10/0,20/1 all can stop erythrocyte deformability decline (P＜0.01) to a certain extent, puerarin/Radix Astragali saponin 11/1,10/1,1/1,3/1 and sham operated rats are approaching, effect best (P＜0.01).Puerarin uses than single with puerarin or single effective with Radix Astragali saponin with the Radix Astragali saponin proportioning.When blocking after 9 days, normal saline group and sham operated rats ratio, erythrocyte deformability further descends.The decline of erythrocyte deformability all can be improved and stop to each administration group and normal saline group ratio, and statistical procedures has significance meaning (P＜0.01), wherein can strengthen erythrocyte deformability with puerarin/Radix Astragali saponin 11/1,10/1,1/1,3/1.Puerarin uses than single with the Radix Astragali saponin proportioning uses Radix Astragali saponin effective with puerarin or list, and effect all is better than commercially available puerarin injection and Radix Astragali injection.
In sum, perform the operation after 2 hours, rat is existing hemorheological unusual.Blocked 3-9 days, hemorheology unusually further increases the weight of, and shows as whole blood viscosity and raises degradation under the erythrocyte deformability.Puerarin and Radix Astragali saponin proportioning medicine can play and improve blood flow Denaturation behind the cerebral infarction, after the 3rd day, then can correct unusual hemorheology significantly and change.And effect with dosage astragaloside or independent the use with the dosage puerarin, also is better than commercially available puerarin injection and Radix Astragali injection significantly better than independent use.Wherein, the best proportioning of effect is a puerarin: astragaloside=10: 1.
The specific embodiment
The present invention is described in further detail below in conjunction with the specific embodiment.
Embodiment one
Get Radix Astragali saponin 10g, puerarin 1g, vegetable oil 21g, mixing is made capsule casing material with gelatin, is pressed into soft capsule, promptly makes the pharmaceutical composition of the soft capsule dosage form that contains 1 part of Radix Astragali saponin and 0.1 part of puerarin.
Embodiment two
Get Radix Astragali saponin 1g, puerarin 20g is dissolved in the 1000ml water for injection, adopts existing preparation of injection, promptly makes the pharmaceutical composition of the injectable powder type that contains 1 part of Radix Astragali saponin and 20 parts of puerarins.
Embodiment three
Get Radix Astragali saponin 10g, puerarin 2g, starch 100g, mix homogeneously adopts capsules preparation technique, promptly makes the pharmaceutical composition of the capsule formulation that contains 1 part of Radix Astragali saponin and 0.2 part of puerarin.
Embodiment four
Get Radix Astragali saponin 1g, puerarin 11g, mix homogeneously adopts drop pill preparation technology, promptly makes the pharmaceutical composition of the drops that contains 1 part of Radix Astragali saponin and 11 parts of puerarins.
Embodiment five
Get Radix Astragali saponin 10g, puerarin 10g, sucrose 80g, mix homogeneously is granulated, and sieves, and drying promptly makes the granule forms of pharmaceutical compositions that contains 1 part of Radix Astragali saponin and 1 part of puerarin; Maybe with the granule that makes through further tabletting, drying promptly makes the pharmaceutical composition of the Tabules that contains 1 part of Radix Astragali saponin and 1 part of puerarin.
Embodiment six
Get Radix Astragali saponin 2g, puerarin 20g, polyethylene 60g, mix homogeneously is granulated, tabletting, drying promptly makes the pharmaceutical composition of the slow releasing tablet dosage form that contains 1 part of puerarin and 10 parts of Radix Astragali saponins.
Embodiment seven
Get Radix Astragali saponin 2g, puerarin 10g is dissolved in the 1000ml water for injection, adopts process for preparation of injection, promptly makes injection (the containing transfusion) forms of pharmaceutical compositions that contains 1 part of Radix Astragali saponin and 1 part of puerarin.
More than the raw material that adopts among each embodiment, the existing sale in the puerarin city; Radix Astragali saponin then can make by following method:
Get Milkvetch Root, use ethanol extraction, collect extracting solution, in the extracting solution after reclaiming ethanol, thin up staticly settles, and filters, and gets supernatant concentration and becomes extractum; Described extractum is crossed macroporous adsorbent resin, and the low-concentration ethanol eluting of first water or 1-20% is removed the impurity that is dissolved in polar solvent, discard need not, the high concentration ethanol eluting of reuse 40-91% is collected this high concentration ethanol eluent, eluent drying with behind the recovery ethanol promptly gets Radix Astragali saponin.
Claims (6)
1, a kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease, it is made up of puerarin and two kinds of raw materials of Radix Astragali saponin of extracting from the Radix Astragali.
2, the pharmaceutical composition of treatment cardiovascular and cerebrovascular disease according to claim 1 is characterized in that: the weight proportion of described two kinds of raw materials is: 1 part of the Radix Astragali saponin that extracts from the Radix Astragali, puerarin 0.1-20 part.
3, the pharmaceutical composition of treatment cardiovascular and cerebrovascular disease according to claim 2 is characterized in that: the weight proportion of described two kinds of raw materials is: 1 part of the Radix Astragali saponin that extracts from the Radix Astragali, puerarin 0.2-15 part.
4, the pharmaceutical composition of treatment cardiovascular and cerebrovascular disease according to claim 3 is characterized in that: the weight proportion of described two kinds of raw materials is: 1 part of the Radix Astragali saponin that extracts from the Radix Astragali, puerarin 2-12 part.
5, the pharmaceutical composition of treatment cardiovascular and cerebrovascular disease according to claim 4 is characterized in that: the weight proportion of described two kinds of raw materials is: 1 part of the Radix Astragali saponin that extracts from the Radix Astragali, 10 parts of puerarins.
6, according to claim 1 or 2 or 3 or the pharmaceutical composition of 4 or 5 described treatment cardiovascular and cerebrovascular disease, it is characterized in that: its dosage form can be any existing pharmaceutical dosage form in injection, transfusion, powder pin, drop pill, tablet, slow releasing tablet, capsule, soft capsule, the granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410022178 CN1562057A (en) | 2004-03-31 | 2004-03-31 | Medicinal composition for treating cardiocerobral diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410022178 CN1562057A (en) | 2004-03-31 | 2004-03-31 | Medicinal composition for treating cardiocerobral diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1562057A true CN1562057A (en) | 2005-01-12 |
Family
ID=34479946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410022178 Pending CN1562057A (en) | 2004-03-31 | 2004-03-31 | Medicinal composition for treating cardiocerobral diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1562057A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101380353B (en) * | 2008-10-20 | 2012-02-01 | 东莞广州中医药大学中医药数理工程研究院 | Pharmaceutical composition for preventing and curing 2-type diabetes and preparation method thereof |
| CN104435664A (en) * | 2014-11-11 | 2015-03-25 | 成都果睿医药科技有限公司 | Red-bean-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases |
| CN116492359A (en) * | 2023-04-12 | 2023-07-28 | 南方医科大学珠江医院 | Composition containing glycosylated puerarin and preparation method and application thereof |
-
2004
- 2004-03-31 CN CN 200410022178 patent/CN1562057A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101380353B (en) * | 2008-10-20 | 2012-02-01 | 东莞广州中医药大学中医药数理工程研究院 | Pharmaceutical composition for preventing and curing 2-type diabetes and preparation method thereof |
| CN104435664A (en) * | 2014-11-11 | 2015-03-25 | 成都果睿医药科技有限公司 | Red-bean-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases |
| CN116492359A (en) * | 2023-04-12 | 2023-07-28 | 南方医科大学珠江医院 | Composition containing glycosylated puerarin and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100447148C (en) | Cape jasmine extract , its preparing process and application | |
| CN105816471B (en) | A kind of notoginseng total saponin compounds and its preparation method and application | |
| CN1256940C (en) | Compound Chinese medicine notoginseng dripping pills and its prepn process | |
| CN101987112B (en) | Medicine composition for treating cardio-cerebrovascular diseases and preparation method thereof | |
| CN1562057A (en) | Medicinal composition for treating cardiocerobral diseases | |
| CN100415241C (en) | Medicinal composition for treating cardio-cerebrovascular diseases | |
| CN1857385B (en) | Medicine composition for treating cervical spondylosis and its preparing method | |
| CN100408045C (en) | Medicinal composition for treating cardio-cerebro-vascular diseases | |
| CN1319549C (en) | Method for extracting general iridoid glycoside from 'Duyiwei' of Tibet medicine and application | |
| CN1255121C (en) | Gadol pharmaceutical preparation, method for making same and uses | |
| CN116898888A (en) | Fresh ginseng active extract and application thereof | |
| CN1528325A (en) | Medicinal composition for treating cardio-cerebro-vascular diseases | |
| CN111558019B (en) | Traditional Chinese medicine composition with effects of benefiting qi, nourishing blood, regulating menstruation and relieving pain and preparation method and application thereof | |
| CN100381125C (en) | Cardiac and cerebral vascular disease treating medicinal composition | |
| CN100484517C (en) | Smash-resisting panax notoginseng total saponin free-dried powdery injection and its preparation | |
| CN102940669B (en) | A pharmaceutical composition for treating cardiovascular and cerebrovascular diseases | |
| CN102940675B (en) | Medicine composition for treating cardia-cerebrovascular diseases | |
| CN101697989A (en) | Application of notoginseng and extract thereof in preparing medicaments for treating and/or preventing coronary artherosclerosis | |
| CN101716253B (en) | Chinese medicinal preparation containing panax notoginseng, and preparation method thereof | |
| CN102940657A (en) | Medicine composition for treating cardia-cerebrovascular diseases | |
| CN111529637A (en) | Medicine for treating cerebral circulation insufficiency, cerebral thrombosis, cerebral infarction and DIC and improving immunity | |
| WO2004098623A1 (en) | A notoginseng saponin intravenous injection and the method for preparing this injection | |
| CN110193024A (en) | The preparation method of serum with overactivity cell factor | |
| CN102940694B (en) | Medicine composition for treating cardia-cerebrovascular diseases | |
| CN103055011A (en) | G6 lectin extracted from traditional Chinese medicines and applications thereof in detoxification, pressure stabilization, blood vessel softening and complication resistance |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Li Wenjun Document name: Notification before expiration of term |
|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Li Wenjun Document name: Deemed as a notice of withdrawal |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |